SB939: A potent and orally-active HDAC inhibitor for the treatment of hematological malignancies
SB939, a novel histone deacetylase HDAC inhibitor with improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors, is currently in Phase I clinical trials, and has demonstrated potential for the treatment of various types of hematological malignancies.
Poster No. 747
SB1317, a potent and orally-active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies
SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia
(AML), and CDK1, 2, and 9 are well-established anti-cancer targets due to their direct role in cell cycle control.
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317, is in pre-clinical development.
In line with its vision to be a leading fully-integrated
oncology-focused biotech company in Asia Pacific, S*BIO has established a
state-of-the-art R&D infrastructure, complemented by a strong clinical
development team. S*BIO has strong linkages with a network of medical
oncologists in Asia Pacific and its investors include Bio*One Capital,
Novartis Bioventures and other international funds. More information about
S*BIO can be found at http://www.sbio.com.
S*BIO Pte Ltd:
Stephen Keith Rhind, Ph.D.
Senior Vice President, Cor
|SOURCE S*BIO Pte Ltd|
Copyright©2007 PR Newswire.
All rights reserved